Table 1. Characteristic of studies.
| Author, year | Study design | Patient characteristics | Sample size | Treatment | Comparator | Median follow-up | Treatment duration (wk) | NOS |
|---|---|---|---|---|---|---|---|---|
| Amali 2015 (13) | RCT | CRS | 63 | Azithromycin 250 mg QD + nasal saline solution irrigation TID + fluticasone nasal spray 2puffs/BID | Nasal saline solution irrigation TID + fluticasone nasal spray 2puffs/BID | Baseline and 12 weeks | 12 | – |
| Deng 2018 (16) | RCT | CRS | 74 | budesonide 64 ìg/spray BID + Clarithromycin 250 mg QD | budesonide 64 ìg/spray BID | Baseline, 4, 8, 12 weeks | 12 | – |
| Jiang 2012 (21) | RCT | CRSsNPs | 53 | Erythromycin (250 mg) + a Chinese herbal medicine placebo capsule BID | Chinese herbal medicine + Erythromycin placebo capsule BID | Baseline, 8 weeks | 8 | – |
| Videler 2011 (11) | RCT | CRSsNPs | 60 | Azithromycin 500 mg QD 3 days, 500 mg QW 11 weeks + nasal saline irrigation BID | Placebo + nasal saline irrigation BID | 6, 12, 14, 24 weeks | 12 | – |
| Wallwork 2006 (17) | RCT | CRSsNPs | 64 | Roxithromycin 150 mg QD | Placebo | 6, 12, 24 weeks | 12 | – |
| Korkmaz 2014 (22) | RCT | CRSwNP | 44 | Clarithromycin 500 mg BID 2 weeks and 250 mg QD 6 weeks + metasone furoate nasal spray 200 ug once daily for 8 weeks | Metasone furoate nasal spray 200 ìg QD | Baseline, 8 weeks | 8 | – |
| Haxel 2015 (12) | RCT | CRS | 58 | Erythromycin 250 mg QD + nasal saline irrigation BID + fluticasone furoate QD | Placebo + nasal saline irrigation BID + fluticasone furoate QD | Baseline, 12, 24 weeks | 12 | – |
| Bewick 2017 (23) | Cohort | CRSsNPs | 54 | Clarithromycin 250 mg + nasal douching + intranasal mometasone (two squirts, each nostril) BID | – | 12, 24 weeks | 12 | 8 |
| Peric 2010 (24) | Cohort | CRSwNPs (atopic and nonatopic) | 40 | Clarithromycin 500 mg QD | – | Baseline, 8weeks | 8 | 8 |
| Li 2014 (25) | Cohort | CRS | 54 | Flixonase two squirts QD + Clarithromycin 250 mg QD + myrtol standardized enteric capsules 300 mg BID + nasal saline irrigation BID | – | Baseline, 12 weeks | 12 | 8 |
| Luo 2014 (26) | Cohort | CRS (CRSsNP and CRSwNP) | 50 | Clarithromycin 250 mg QD | – | Baseline, 8, 12 weeks | 12 | 8 |
NOS, Newcastle-Ottawa Scale; CRS, chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps.